Brain implant for tinnitus is not coming after all
Egnach, October 17, 2023 – The brain implant against tinnitus announced by the company Neuralink will not be coming after all. They are focusing their research on the area of paralysis and are now beginning the clinical study after receiving approval from the U.S. Food and Drug Administration (FDA). Commercial use will not be available for at least 10 years and that will only be for the area of paralysis.
Once again, the expectations of tinnitus patients have been disappointed. Only last year, research on the OTO-313 medication from the American company Otonomy Inc. was stopped after the second clinical study, as the placebo showed a better effect in patients. Thus, tinniwell remains the only study-proven therapy for tinnitus worldwide.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for inquiries:
Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668